收藏切换
Retrospective study on Shenyan Kangfu tablet in the treatment of diabetes kidney disease
收藏切换
Yuan XU1, Jia WANG2, Yanhui YANG3, Rong LI4, Hu YANG4, Chunyan SHAN3, *
World Clinical Drug | 2024, 45(10) : 1078 - 1084
Less
收藏切换
World Clinical Drug | 2024, 45(10): 1078-1084
• Article •
Retrospective study on Shenyan Kangfu tablet in the treatment of diabetes kidney disease
Full
Yuan XU1, Jia WANG2, Yanhui YANG3, Rong LI4, Hu YANG4, Chunyan SHAN3, *
Affiliations
  • 1.Department of Nephrology, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510030, Guangdong Province, China
  • 2.Tianjin Tongrentang Group Co., LTD., Tianjin 300380, China
  • 3.Department of Nephrology, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology of Tianjin Medical University, NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Tianjin 300134, China
  • 4.Department of Nephrology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
Published: 2024-10-10 doi: 10.13683/j.wph.2024.10.013
Outline
收藏切换
Objective

To collect the medical records of patients with diabetic kidney disease (DKD) during the course of Shenyan Kangfu tablets, and to analyze the clinical features of Shenyan Kangfu tablets in the treatment of DKD and the improvement of renal function in the real world.

Methods

Based on the hospital electronic medical record information system, 503 cases of DKD patients with prescription Shenyan Kangfu tablets from October 1, 2016 to October 31, 2021 were collected to analyze the characteristics of the population taking Shenyan Kangfu tablets in the real world, the distribution of drug diseases, the improvement of renal function, the safety and the combined treatment plan, and to evaluate its efficacy and safety.

Results

The age of DKD patients taking Shenyan Kangfu tablets was mainly 30~80 years old, of which 50~60 years old accounted for 33.20% and 60~70 years old accounted for 30.22%. There were more males than females (67.40% vs 32.60%). The results showed that Shenyan Kangfu tablets could significantly reduce urinary protein, urinary albumin/creatinine ratio (ACR), glycosylated hemoglobin (Hb) A1c and other indexes at 24 h. After taking Shenyan Kangfu tablets for 3 months, 24 h urinary protein level increased, hemoglobin, serum albumin, HbA1c levels decreased. During 3 to 6 months, 24 h urinary protein, creatinine and HbA1c levels decreased. After 6 months, ACR levels increased and 24 h urinary protein and HbA1c levels decreased. No adverse reactions were recorded during the administration, and the safety was good. Clinical drug combinations mainly include blood glucose control drugs, blood pressure control drugs, lipid-regulating drugs, etc.

Conclusion

There are more DKD patients using Shenyan Kangfu tablet in clinical practice, and the preliminary results show that Shenyan Kangfu tablet combined with conventional western medicine treatment of DKD is safe and effective.

Shenyan Kangfu tablet  /  diabetic kidney disease  /  retrospective study
许苑, 王佳, 杨艳辉, 李荣, 杨虎, 单春艳. 肾炎康复片治疗糖尿病肾病回顾性临床分析. 世界临床药物, 2024 , 45 (10) : 1078 -1084 . DOI: 10.13683/j.wph.2024.10.013
Yuan XU, Jia WANG, Yanhui YANG, Rong LI, Hu YANG, Chunyan SHAN. Retrospective study on Shenyan Kangfu tablet in the treatment of diabetes kidney disease[J]. World Clinical Drug, 2024 , 45 (10) : 1078 -1084 . DOI: 10.13683/j.wph.2024.10.013
Year 2024 volume 45 Issue 10
9
0
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.10.013
  • Receive Date:2024-05-18
  • Online Date:2026-11-17
  • Published:2024-10-10
Article Data
Affiliations
History
  • Received:2024-05-18
  • Revised:2024-08-20
Funding
Affiliations
    1.Department of Nephrology, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510030, Guangdong Province, China
    2.Tianjin Tongrentang Group Co., LTD., Tianjin 300380, China
    3.Department of Nephrology, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology of Tianjin Medical University, NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Tianjin 300134, China
    4.Department of Nephrology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.10.013
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT